Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Inclusion Criteria:

- Biologic high risk Multiple Myeloma:

- Stage II/III Multiple Myeloma, any of: t(4; 14), t(14; 16),(14:20) by Fish; 17P-
by conventional cytogenetics or Fish; ∆13 by conventional cytogenetics;
Hypodiploidy by conventional cytogenetics.

- Relapsed or persistent multiple myeloma after ASCT.

- Persistent multiple myeloma, regardless of previous therapies.

- Plasma cell leukemia, regardless of previous therapies.

- Age up to 70 years old (less than 71 years old at the date of transplant admission).

- Disease status: in CR, nCR, VGPR, PR or stable disease within 1 month of admission

- Patients with non-secretory and oligosecretory disease are eligible if they meet
certain criteria within 2 weeks prior to the transplant.

- Specific renal, liver, cardiac, and pulmonary function requirements(all must be met
within 30 days of transplant admission)

Exclusion Criteria:

- Persistent invasive infections, not controlled by antimicrobials.

- HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity.

- Uncontrolled medical or psychiatric disorder.

- No response or progressive disease at the time of transplantation.

- Pregnancy